Altium Capital Management LP Amylyx Pharmaceuticals, Inc. Transaction History

Altium Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $5.01 Million - $7.66 Million	-415,174 Reduced 77.65%	119,526 $1.76 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $6.32 Million - $8.2 Million	349,700 Added 189.03%	534,700 $9.79 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $1.25 Million - $1.84 Million	45,000 Added 32.14%	185,000 $5.43 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $3.12 Million - $4.12 Million	105,000 Added 300.0%	140,000 $5.17 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $600,250 - $1.08 Million	35,000 New	35,000 $985,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $237M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.